利妥昔单抗对ANCA相关性血管炎患者恶性肿瘤风险的影响
该研究纳入2000至2014年间在三级血管炎转诊中心治疗的323例ANCA相关性血管炎患者,比较利妥昔单抗与环磷酰胺治疗者的恶性肿瘤发生率。结果显示环磷酰胺治疗者恶性肿瘤风险显著高于一般人群(SIR 3.10),而利妥昔单抗治疗者与一般人群相似(SIR 0.67),且环磷酰胺治疗者恶性肿瘤风险是利妥昔单抗治疗者的4.61倍。
要点
- AAV患者总体恶性肿瘤风险升高,主要由非黑色素瘤皮肤癌驱动。
- 环磷酰胺治疗者恶性肿瘤风险显著高于一般人群(SIR 3.10)。
- 利妥昔单抗治疗者恶性肿瘤风险与一般人群相似(SIR 0.67)。
核心结论
- 利妥昔单抗治疗的AAV患者恶性肿瘤风险低于环磷酰胺治疗者,且与一般人群相比未增加恶性肿瘤风险。
研究设计与样本
- 研究纳入2000至2014年间在三级血管炎转诊中心治疗的323例AAV患者,比较其恶性肿瘤发生率与一般人群,并比较利妥昔单抗治疗与环磷酰胺治疗患者间的恶性肿瘤发生率。
主要发现
- 323例患者平均随访5.6年,33例发生共45种恶性肿瘤,总体恶性肿瘤风险为一般人群的1.89倍(95% CI 1.38至2.53)。
- 排除非黑色素瘤皮肤癌后恶性肿瘤风险未见显著升高(SIR 1.09;95% CI 0.67至1.69)。
- 非黑色素瘤皮肤癌风险为一般人群的4.58倍(95% CI 2.96至6.76)。
- 环磷酰胺治疗者恶性肿瘤风险显著高于一般人群(SIR 3.10;95% CI 2.06至4.48),而利妥昔单抗治疗者与一般人群相似(SIR 0.67;95% CI 0.08至2.43)。
- 环磷酰胺治疗者恶性肿瘤风险是利妥昔单抗治疗者的4.61倍(95% CI 1.16至39.98)。
临床怎么用
- 在AAV治疗中,利妥昔单抗可作为环磷酰胺的安全替代选择,以降低恶性肿瘤风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with cyclophosphamide have an increased malignancy risk compared with the general population. We investigated whether treatment with rituximab instead of cyclophosphamide has decreased the malignancy risk in patients with AAV. METHODS: The study included patients with AAV treated at a tertiary vasculitis referral centre between 2000 and 2014. The malignancy incidence in these patients was compared with the incidence in the general population by calculating standardised incidence ratios (SIRs), adjusted for sex, age and calendar year. Malignancy incidence was compared between rituximab-treated and cyclophosphamide-treated patients. RESULTS: Of the 323 included patients, 33 developed a total of 45 malignancies during a mean follow-up of 5.6 years. This represented a 1.89-fold increased (95% CI 1.38 to 2.53) malignancy risk, and a non-significantly increased risk if non-melanoma skin cancer was excluded (SIR, 1.09; 95% CI 0.67 to 1.69). The risk of non-melanoma skin cancer was 4.58-fold increased (95% CI 2.96 to 6.76). Cyclophosphamide-treated patients had an increased malignancy risk compared with the general population (SIR, 3.10; 95% CI 2.06 to 4.48). In contrast, rituximab-treated patients had a malignancy risk similar to the general population (SIR, 0.67; 95% CI 0.08 to 2.43). The malignancy risk in cyclophosphamide-treated patients was 4.61-fold higher (95% CI 1.16 to 39.98) than in rituximab-treated patients. CONCLUSIONS: The malignancy risk in patients with AAV was lower in rituximab-treated patients than in cyclophosphamide-treated patients. Notably, rituximab treatment was not associated with an increased malignancy risk compared with the general population. Rituximab could therefore be a safe alternative to cyclophosphamide in the treatment of AAV.
引用
- van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2016. PMID: 27899372. doi:10.1136/annrheumdis-2016-209925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。